Loading…
Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development
Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed i...
Saved in:
Published in: | Translational oncology 2018-08, Vol.11 (4), p.1012-1022 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123 |
---|---|
cites | cdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123 |
container_end_page | 1022 |
container_issue | 4 |
container_start_page | 1012 |
container_title | Translational oncology |
container_volume | 11 |
creator | Gu, Yan Chow, Mathilda Jing Kapoor, Anil Mei, Wenjuan Jiang, Yanzhi Yan, Judy De Melo, Jason Seliman, Maryam Yang, Huixiang Cutz, Jean-Claude Bonert, Michael Major, Pierre Tang, Damu |
description | Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC. |
doi_str_mv | 10.1016/j.tranon.2018.06.003 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ce0975da21d74fe09836967cf0c25677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1936523318301888</els_id><doaj_id>oai_doaj_org_article_ce0975da21d74fe09836967cf0c25677</doaj_id><sourcerecordid>2063719440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhlcIREvhHyC0x_aQxZ-z6wtSk7ZQqRIcgKtl7NnE0WYdbG-k_Hsc0pb2gmTJHzPzjud9quo9JQ0lFD6umxzNGMaGEdo1BBpC-IvqlCoOM8k4f_nkfFK9SWlNCFDF2OvqhCkF0IE4rX7O_XZlkrf15ZAxmuzDWIe-nk95H_eDXYXBj5gOoYT1-Xyxur6or6box2X9LYaUTcZ6YUaLsb7CHQ5hu8Exv61e9WZI-O5-P6t-3Fx_X3yZ3X39fLu4vJtZqWSecQq2LGup48Zw6EXfKYPcqB4ACKOdErSjzChwnZMtYcQKJ1UvOqcsZfysuj3qumDWehv9xsS9Dsbrvw8hLrWJ2dsBtUWiWukMo64Vfbl0HBS0tieWSWjbovXpqLWdfm3Q2TJGNMMz0eeR0a_0Muw0EE6ZlEXg_F4ght9TMU1vfLI4DGbEMCXNCPCWKiFISRXHVFs8TBH7xzaU6ANevdZHvPqAVxPQBW8p-_D0i49FDzz_zYDF9J3HqJP1WOg4H9Hm4or_f4c_UBe4uQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2063719440</pqid></control><display><type>article</type><title>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Gu, Yan ; Chow, Mathilda Jing ; Kapoor, Anil ; Mei, Wenjuan ; Jiang, Yanzhi ; Yan, Judy ; De Melo, Jason ; Seliman, Maryam ; Yang, Huixiang ; Cutz, Jean-Claude ; Bonert, Michael ; Major, Pierre ; Tang, Damu</creator><creatorcontrib>Gu, Yan ; Chow, Mathilda Jing ; Kapoor, Anil ; Mei, Wenjuan ; Jiang, Yanzhi ; Yan, Judy ; De Melo, Jason ; Seliman, Maryam ; Yang, Huixiang ; Cutz, Jean-Claude ; Bonert, Michael ; Major, Pierre ; Tang, Damu</creatorcontrib><description>Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.</description><identifier>ISSN: 1936-5233</identifier><identifier>EISSN: 1936-5233</identifier><identifier>DOI: 10.1016/j.tranon.2018.06.003</identifier><identifier>PMID: 29966864</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Original article</subject><ispartof>Translational oncology, 2018-08, Vol.11 (4), p.1012-1022</ispartof><rights>2018 The Authors</rights><rights>Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>2018 The Authors 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</citedby><cites>FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</cites><orcidid>0000-0001-6519-4879</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031255/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1936523318301888$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29966864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Yan</creatorcontrib><creatorcontrib>Chow, Mathilda Jing</creatorcontrib><creatorcontrib>Kapoor, Anil</creatorcontrib><creatorcontrib>Mei, Wenjuan</creatorcontrib><creatorcontrib>Jiang, Yanzhi</creatorcontrib><creatorcontrib>Yan, Judy</creatorcontrib><creatorcontrib>De Melo, Jason</creatorcontrib><creatorcontrib>Seliman, Maryam</creatorcontrib><creatorcontrib>Yang, Huixiang</creatorcontrib><creatorcontrib>Cutz, Jean-Claude</creatorcontrib><creatorcontrib>Bonert, Michael</creatorcontrib><creatorcontrib>Major, Pierre</creatorcontrib><creatorcontrib>Tang, Damu</creatorcontrib><title>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</title><title>Translational oncology</title><addtitle>Transl Oncol</addtitle><description>Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.</description><subject>Original article</subject><issn>1936-5233</issn><issn>1936-5233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kU1vEzEQhlcIREvhHyC0x_aQxZ-z6wtSk7ZQqRIcgKtl7NnE0WYdbG-k_Hsc0pb2gmTJHzPzjud9quo9JQ0lFD6umxzNGMaGEdo1BBpC-IvqlCoOM8k4f_nkfFK9SWlNCFDF2OvqhCkF0IE4rX7O_XZlkrf15ZAxmuzDWIe-nk95H_eDXYXBj5gOoYT1-Xyxur6or6box2X9LYaUTcZ6YUaLsb7CHQ5hu8Exv61e9WZI-O5-P6t-3Fx_X3yZ3X39fLu4vJtZqWSecQq2LGup48Zw6EXfKYPcqB4ACKOdErSjzChwnZMtYcQKJ1UvOqcsZfysuj3qumDWehv9xsS9Dsbrvw8hLrWJ2dsBtUWiWukMo64Vfbl0HBS0tieWSWjbovXpqLWdfm3Q2TJGNMMz0eeR0a_0Muw0EE6ZlEXg_F4ght9TMU1vfLI4DGbEMCXNCPCWKiFISRXHVFs8TBH7xzaU6ANevdZHvPqAVxPQBW8p-_D0i49FDzz_zYDF9J3HqJP1WOg4H9Hm4or_f4c_UBe4uQ</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Gu, Yan</creator><creator>Chow, Mathilda Jing</creator><creator>Kapoor, Anil</creator><creator>Mei, Wenjuan</creator><creator>Jiang, Yanzhi</creator><creator>Yan, Judy</creator><creator>De Melo, Jason</creator><creator>Seliman, Maryam</creator><creator>Yang, Huixiang</creator><creator>Cutz, Jean-Claude</creator><creator>Bonert, Michael</creator><creator>Major, Pierre</creator><creator>Tang, Damu</creator><general>Elsevier Inc</general><general>Neoplasia Press</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6519-4879</orcidid></search><sort><creationdate>20180801</creationdate><title>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</title><author>Gu, Yan ; Chow, Mathilda Jing ; Kapoor, Anil ; Mei, Wenjuan ; Jiang, Yanzhi ; Yan, Judy ; De Melo, Jason ; Seliman, Maryam ; Yang, Huixiang ; Cutz, Jean-Claude ; Bonert, Michael ; Major, Pierre ; Tang, Damu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Original article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Yan</creatorcontrib><creatorcontrib>Chow, Mathilda Jing</creatorcontrib><creatorcontrib>Kapoor, Anil</creatorcontrib><creatorcontrib>Mei, Wenjuan</creatorcontrib><creatorcontrib>Jiang, Yanzhi</creatorcontrib><creatorcontrib>Yan, Judy</creatorcontrib><creatorcontrib>De Melo, Jason</creatorcontrib><creatorcontrib>Seliman, Maryam</creatorcontrib><creatorcontrib>Yang, Huixiang</creatorcontrib><creatorcontrib>Cutz, Jean-Claude</creatorcontrib><creatorcontrib>Bonert, Michael</creatorcontrib><creatorcontrib>Major, Pierre</creatorcontrib><creatorcontrib>Tang, Damu</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Yan</au><au>Chow, Mathilda Jing</au><au>Kapoor, Anil</au><au>Mei, Wenjuan</au><au>Jiang, Yanzhi</au><au>Yan, Judy</au><au>De Melo, Jason</au><au>Seliman, Maryam</au><au>Yang, Huixiang</au><au>Cutz, Jean-Claude</au><au>Bonert, Michael</au><au>Major, Pierre</au><au>Tang, Damu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development</atitle><jtitle>Translational oncology</jtitle><addtitle>Transl Oncol</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>11</volume><issue>4</issue><spage>1012</spage><epage>1022</epage><pages>1012-1022</pages><issn>1936-5233</issn><eissn>1936-5233</eissn><abstract>Butyrylcholinesterase (BChE) is a plasma enzyme that hydrolyzes ghrelin and bioactive esters, suggesting a role in modulating metabolism. Serum BChE is reduced in cancer patients. In prostate cancer (PC), the down-regulation is associated with disease recurrence. Nonetheless, how BChE is expressed in PC and its impact on PC remain unclear. We report here the biphasic changes of BChE expression in PC. In vitro, BChE expression was decreased in more tumorigenic PC stem-like cells (PCSLCs), DU145, and PC3 cells compared to less tumorigenic non-stem PCs and LNCaP cells. On the other hand, BChE was expressed at a higher level in LNCaP cells than immortalized but non-tumorigenic prostate epithelial BPH-1 cells. In vivo, BChE expression was up-regulated in DU145 xenografts compared to LNCaP xenografts; DU145 cell-derived lung metastases displayed comparable levels of BChE as subcutaneous tumors. Furthermore, LNCaP xenografts produced in castrated mice exhibited a significant increase of BChE expression compared to xenografts generated in intact mice. In patients, BChE expression was down-regulated in PCs (n = 340) compared to prostate tissues (n = 86). In two independent PC populations MSKCC (n = 130) and TCGA Provisional (n = 490), BChE mRNA levels were reduced from World Health Organization grade group 1 (WHOGG 1) PCs to WHOGG 3 PCs, followed by a significant increase in WHOGG 5 PCs. The up-regulation was associated with a reduction in disease-free survival (P = .008). Collectively, we demonstrated for the first time a biphasic alteration of BChE, its down-regulation at early stage of PC and its up-regulation at advanced PC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29966864</pmid><doi>10.1016/j.tranon.2018.06.003</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6519-4879</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1936-5233 |
ispartof | Translational oncology, 2018-08, Vol.11 (4), p.1012-1022 |
issn | 1936-5233 1936-5233 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_ce0975da21d74fe09836967cf0c25677 |
source | ScienceDirect Journals; PubMed Central |
subjects | Original article |
title | Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A58%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biphasic%20Alteration%20of%20Butyrylcholinesterase%20(BChE)%20During%20Prostate%20Cancer%20Development&rft.jtitle=Translational%20oncology&rft.au=Gu,%20Yan&rft.date=2018-08-01&rft.volume=11&rft.issue=4&rft.spage=1012&rft.epage=1022&rft.pages=1012-1022&rft.issn=1936-5233&rft.eissn=1936-5233&rft_id=info:doi/10.1016/j.tranon.2018.06.003&rft_dat=%3Cproquest_doaj_%3E2063719440%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c595t-316c16ccc1d3aa36f4f89ae3a9f6660218941812a96d8d57020c4d59f48d9c123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2063719440&rft_id=info:pmid/29966864&rfr_iscdi=true |